NPPB and cardiac hypertrophy: On the contrary, overexpression of Foxo6os (Figure S2C,D, Supporting Information) in Ang II‐treated cardiomyocytes could postpone the progression of cardiac hypertrophy, manifesting a significant reduction in the levels of ANP, BNP, and MYH7 compared to the control group (Figure 4G,H), and further confirmed by immunofluorescence (IF) staining (Figure 4I,J,K).